NCT03777332View on ClinicalTrials.gov

Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

April 1, 2021

Study Completion Date

April 1, 2021

Conditions
Geographic Atrophy
Interventions
DRUG

PEGCETACOPLAN (APL-2)

Complement (C3) Inhibitor

Trial Locations (5)

77384

Retina Consultants of Houston, The Woodlands

90211

Retina Vitreous Associates Medical Group, Beverly Hills

91436

The Retina Partners, Encino

93309

California Retina Consultants, Bakersfield

02114

Ophthalmic Consultants of Boston, Boston

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY

NCT03777332 - Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy | Biotech Hunter | Biotech Hunter